Уважаемые коллеги!
Не касаясь святого - нашего отношения к термину "дизбактериоз", тем не менее меня все-таки смущает несколько однобокий подход в рекомендациях по применению пробиотиков. Я в своих консультациях стараюсь обходить этот вопрос, как Вы заметили.
Вчера прочитал статью, которую хочу предложить Вашему вниманию без перевода (он не сложен). Хотя, если есть необходимость, то и перевод сделаю.
Прошу высказать отношение к предмету обсуждения. Конечная цель обсуждения - выработать единый подход к рекомендациям по назначению пробиотиков в различных ситуациях.
------------------------------------------
[Ссылки доступны только зарегистрированным пользователям ]
Benefits of Probiotics Reviewed CME/CE
News Author: Laurie Barclay, MD
CME Author: Laurie Barclay, MD
Authors and Disclosures
Laurie Barclay, MD
Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.Laurie Scudder, MS, NP-C
Disclosure: Laurie Scudder, MS, NP-C, has disclosed no relevant financial information. Brande Nicole Martin
Disclosure: Brande Nicole Martin has disclosed no relevant financial information.
November 6, 2008 — Probiotics are microorganisms that may be helpful for conditions such as antibiotic-associated diarrhea, infectious diarrhea, irritable bowel syndrome, and atopic dermatitis in at-risk infants, according to a review published in the November 1 issue of American Family Physician.
"Probiotics are live microorganisms that benefit the health of the host when administered in adequate amounts," write Benjamin Kligler, MD, MPH, from Albert Einstein College of Medicine of Yeshiva University, and Andreas Cohrssen, MD, from the Beth Israel Residency Program in Urban Family Practice, both in New York, New York. "Several mechanisms have been proposed to explain the actions of probiotics. In most cases, it is likely that more than one mechanism is at work simultaneously."
Because of these multiple mechanisms of action, many different probiotics have potential applications to various diseases. Those in most widespread use, which have undergone the most clinical testing, include Lactobacillus species (such as L acidophilus, L rhamnosus, L bulgaricus, L reuteri, and L casei); Bifidobacterium species; and Saccharomyces boulardii, which is a nonpathogenic yeast.
Efficacy of a probiotic species taken orally requires that it be resistant to acid and bile so that it can pass through the upper gastrointestinal tract without loss of biological potency. However, even the hardiest microorganisms must be administered regularly to maintain colonization and typically can no longer be cultured from stool samples more than 1 to 2 weeks after ingestion of the probiotic.
Probiotics are considered to be both safe and effective for preventing and treating antibiotic-associated diarrhea and infectious diarrhea. The probable mechanism of action may be a combination of direct competition between pathogenic bacteria in the gut and immune modulation and enhancement.
Other specific applications supported to some degree by available studies include relief of gastrointestinal tract symptoms in irritable bowel syndrome and therapy for pediatric atopic dermatitis.
Although probiotics are sometimes used for other conditions, evidence is lacking to support these indications, and they were therefore not discussed in this review. These conditions include vaginal candidiasis, stomach infection with Helicobacter pylori, inflammatory bowel disease, and upper respiratory tract infections.
On the basis of dosages used in clinical studies documenting efficacy, frequently used dosages range from 5 to 10 billion colony-forming units per day for children and from 10 to 20 billion colony-forming units per day for adults, although these vary based on the specific microorganism or combination used. In most studies, the dosages of S boulardii range from 250 to 500 mg/day.
Probiotics have no reported drug interactions. Common adverse effects are mild and self-limited, including flatulence and mild abdominal discomfort. Septicemia and other severe adverse effects may rarely occur, and these have only been reported in severely ill or immunocompromised hosts or in children with short-gut syndrome. Therefore, probiotics should be used only with caution in patients with short-gut syndrome, and they are contraindicated in patients with conditions that severely compromise the immune system.
Available formulations of probiotics include capsules, powder, tablets, liquid, or incorporated into food.
The cost of probiotic therapy ranges from $8 to $22 for a 1-month supply. For information regarding the quality of different products, clinicians should consult the Consumer Lab Web site or other objective sources. Other useful Web sites are usprobiotics.org and the National Center for Complementary and Alternative Medicine's Web site.
Specific clinical recommendations, and their accompanying level of evidence rating, are as follows:
• Probiotics may help prevent antibiotic-related diarrhea (level of evidence, A). For this indication, use of S boulardii and L rhamnosus GG are best supported by the available evidence.
• In a recent meta-analysis, probiotics reduced the risk for the development of antibiotic-associated diarrhea by 52%, and the benefit was greatest when probiotic therapy was initiated within 72 hours of starting antibiotic treatment.
• In all-cause infectious diarrhea, probiotic therapy may decrease both the duration of illness and the severity of symptoms, based on a large Cochrane review and meta-analysis including studies of viral diarrhea and traveler's diarrhea (level of evidence, A).
• In that review, probiotics were associated with a significant (34%) reduction in the risk for diarrhea at 3 days, and the mean duration of diarrhea was reduced by approximately 30 hours, leading the authors to conclude that probiotics may be a useful adjunct to rehydration therapy in treating acute infectious diarrhea in adults and children.
• In patients with irritable bowel syndrome, probiotic therapy may decrease the severity of pain and abdominal bloating, based on small studies performed thus far (level of evidence, B).
• For at-risk infants, probiotics may help prevent atopic dermatitis (level of evidence, B), and some preliminary evidence suggests that symptoms of atopic dermatitis may also respond to probiotic therapy.
"Because some labels are unreliable, physicians should recommend specific brands known to be of reasonable quality or encourage patients to research brands before purchasing a specific product," the review authors conclude. "For patients who dislike taking pills or powder, therapeutic yogurt preparations may be preferred option....More studies are warranted on many food sources of probiotics to provide confidence in effectiveness and dose recommendations."
The review authors have disclosed no relevant financial relationships.Am Fam Physician. 2008;78:1073-1078.